Plenary:

M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. Hecht, S. Gallinger, H. Au, K. Ding, J. Christy-Bittel, and W. Parulekar

Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]
J Clin Oncol (Meeting Abstracts) 2005 23: 1. [Abstract]  

B. J. Giantonio, P. J. Catalano, N. J. Meropol, P. J. O’Dwyer, E. P. Mitchell, S. R. Alberts, M. A. Schwartz, and A. B. Benson

High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
J Clin Oncol (Meeting Abstracts) 2005 23: 2. [Abstract]  

J. R. Hecht, T. Trarbach, E. Jaeger, J. Hainsworth, R. Wolff, K. Lloyd, G. Bodoky, M. Borner, D. Laurent, and C. Jacques

A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)
J Clin Oncol (Meeting Abstracts) 2005 23: LBA3. [Abstract]  

A. B. Sandler, R. Gray, J. Brahmer, A. Dowlati, J. H. Schiller, M. C. Perry, and D. H. Johnson

Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599
J Clin Oncol (Meeting Abstracts) 2005 23: LBA4. [Abstract]  

A. F. List, G. Dewald, J. Bennett, A. Giagounadis, A. Raza, E. Feldman, B. Powell, P. Greenberg, J. Zeldis, and R. Knight

Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study
J Clin Oncol (Meeting Abstracts) 2005 23: 5. [Abstract]  

E. F. Attiyeh, Y. P. Mosse, Q. Wang, C. Winter, D. Khazi, G. Hii, P. W. McGrady, K. K. Matthay, W. B. London, and J. M. Maris

Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children’s Oncology Group study
J Clin Oncol (Meeting Abstracts) 2005 23: 6. [Abstract]  

M. C. Heinrich, J. S. Shoemaker, C. L. Corless, D. Hollis, G. D. Demetri, M. M. Bertagnolli, and J. A. Fletcher

Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+)
J Clin Oncol (Meeting Abstracts) 2005 23: 7. [Abstract]  

E. van Cutsem, R. Labianca, D. Hossfeld, G. Bodoky, A. Roth, E. Aranda, B. Nordlinger, S. Assadourian, K. Wang, D. Cunningham PETACC 3

Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)
J Clin Oncol (Meeting Abstracts) 2005 23: LBA8. [Abstract]  

K. C. Oeffinger, A. C. Mertens, C. A. Sklar, T. Kawashima, M. M. Hudson, A. Meadows, N. Marina, N. Kadan-Lottick, W. Leisenring, and L. L. Robison

Prevalence and severity of chronic diseases in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
J Clin Oncol (Meeting Abstracts) 2005 23: 9. [Abstract]  

R. T. Chlebowski, G. L. Blackburn, R. E. Elashoff, C. Thomson, M. T. Goodman, A. Shapiro, A. E. Giuliano, N. Karanja, M. K. Hoy, D. W. Nixon The WINS Investigators

Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women’s Intervention Nutrition Study (WINS)
J Clin Oncol (Meeting Abstracts) 2005 23: 10. [Abstract]  

Breast Cancer:

A. Robinson, S. Ellard, C. Speers, D. Turbin, E. Yorida, A. Rajput, T. Thomson, D. Huntsman, and K. Gelmon

Clinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 500. [Abstract]  

G. A. Milano, W. Lescaut, J. L. Formento, R. Largillier, M. Campone, E. Chamorey, M. Francoual, and J. M. Ferrero

HER2 genetic polymorphism and pharmacodynamics of trastuzumab-based treatment in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2005 23: 501. [Abstract]  

S. Braun, F. D. Vogl, K. Pantel Collaborative Group Bone Marrow Micrometastasis

Disseminated tumor cells (DTC) in bone marrow (BM) and clinical outcome: Final results of pooled analysis on 10-year survival of 4,703 breast cancer patients
J Clin Oncol (Meeting Abstracts) 2005 23: 502. [Abstract]  

G. T. Budd, M. Cristofanilli, M. J. Ellis, A. Stopeck, J. Matera, M. C. Miller, G. V. Doyle, W. J. Allard, L. W. Terstappen, and D. F. Hayes

Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2005 23: 503. [Abstract]  

K. H. Tkaczuk, D. A. Vanecho, N. Tait, F. Feldman, Z. P. Lum, S. Lesko, and P. O.-P. Ts’o

Circulating cancer cells (CCC) in breast cancer (BC) patients
J Clin Oncol (Meeting Abstracts) 2005 23: 504. [Abstract]  

N. Harbeck, I. Bohlmann, J. S. Ross, R. Gruetzmann, G. Kristiansen, A. Margossian, A. Hartmann, T. Cufer, A. Paradiso, S. Maier EpiBreast Group

Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue
J Clin Oncol (Meeting Abstracts) 2005 23: 505. [Abstract]  

C. Sotiriou, P. Wirapati, S. Loi, C. Desmedt, A. L. Harris, J. Bergh, J. Smeds, F. Cardoso, M. Delorenzi, and M. Piccart

Molecular characterization of clinical grade in breast cancer (BC) challenges the existence of "grade 2" tumors
J Clin Oncol (Meeting Abstracts) 2005 23: 506. [Abstract]  

P. L. Porter, W. Barlow, I.-T. Yeh, M.-G. Lin, X. Yuan, J. N. Ingle, C. L. Shapiro, G. P. Sledge, R. B. Livingston, and D. F. Hayes

Prognostic value of cell cycle regulators p27 and cyclin E: Tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313
J Clin Oncol (Meeting Abstracts) 2005 23: 507. [Abstract]  

J. E. Garber, S. Halabi, E. Kaplan, S. Edge, L. Dressler, E. Paskett, N. Berliner Cancer and Leukemia Group B

Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen
J Clin Oncol (Meeting Abstracts) 2005 23: 508. [Abstract]  

S. Loi, M. Piccart, B. Haibe-Kains, C. Desmedt, A. L. Harris, J. Bergh, A. Tutt, L. D. Miller, E. T. Liu, and C. Sotiriou

Prediction of early distant relapses on tamoxifen in early-stage breast cancer (BC): A potential tool for adjuvant aromatase inhibitor (AI) tailoring
J Clin Oncol (Meeting Abstracts) 2005 23: 509. [Abstract]  

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, D. Watson, J. Bryant, J. Costantino, and N. Wolmark

Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 510. [Abstract]  

B. J. Thurlimann, A. Keshaviah, H. Mouridsen, L. Mauriac, J. F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R. D. Gelber, I. Smith, and A. Goldhirsch

BIG 1–98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 511. [Abstract]  

L. J. Goldstein, A. O’Neill, J. Sparano, E. Perez, L. Shulman, S. Martino, and N. Davidson

E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 512. [Abstract]  

L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, P. Valagussa, G. Bonadonna ECTO Study Group

European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)
J Clin Oncol (Meeting Abstracts) 2005 23: 513. [Abstract]  

R. Kochhar, V. Khurana, H. Bejjanki, G. Caldito, and C. Fort

Statins to reduce breast cancer risk: A case control study in U.S. female veterans
J Clin Oncol (Meeting Abstracts) 2005 23: 514. [Abstract]  

W. Y. Chen, W. C. Willett, B. Rosner, and G. A. Coldtiz

Moderate alcohol consumption and breast cancer risk
J Clin Oncol (Meeting Abstracts) 2005 23: 515. [Abstract]  

N. N. Baxter, B. A. Virnig, S. B. Durham, and T. M. Tuttle

Radiation after lumpectomy for DCIS to reduce the risk of invasive breast cancer: A population-based study
J Clin Oncol (Meeting Abstracts) 2005 23: 516. [Abstract]  

I. Wapnir, S. Anderson, E. Mamounas, C. Geyer, J. Hyeon-Jeong, J. Costantino, B. Fisher, and N. Wolmark

Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23
J Clin Oncol (Meeting Abstracts) 2005 23: 517. [Abstract]  

M. Schaapveld, P. H. B. Willemse, E. G. E. de Vries, W. T. A. van der Graaf, O. Visser, M. J. Louwman, R. Otter, J. W. W. Coebergh, and F. E. van Leeuwen

The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer occurrence: A population-based study
J Clin Oncol (Meeting Abstracts) 2005 23: 518. [Abstract]  

A. Goyal, R. G. Newcombe, R. E. Mansel ALMANAC Trialists Group

Clinical relevance of internal mammary node drainage in sentinel node biopsy for breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 519. [Abstract]  

M. O. Leach The collaborators in the MARIBS Study

Screening in women at genetic risk of breast cancer: Results of the UK multicentre study of magnetic resonance imaging (MRI) and X-ray mammography (XRM)
J Clin Oncol (Meeting Abstracts) 2005 23: 520. [Abstract]  

N. Katsumata, H. Minami, K. Aogi, T. Tabei, M. Sano, N. Masuda, J. Andoh, T. Ikeda, N. Ishizuka, and S. Takashima

Phase III trial of doxorubicin (A)/cyclophosphamide (C) (AC), docetaxel (D), and alternating AC and D (AC-D) as front-line chemotherapy for metastatic breast cancer (MBC): Japan Clinical Oncology Group trial (JCOG9802)
J Clin Oncol (Meeting Abstracts) 2005 23: 521. [Abstract]  

A. Gennari, P. Conte, O. Nanni, L. Manzione, E. Cortesi, C. Boni, L. Del Mastro, P. Bruzzi, V. Lo Russo, M. de Lena, and D. Amadori

Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study
J Clin Oncol (Meeting Abstracts) 2005 23: 522. [Abstract]  

M. Cristofanilli, G. T. Budd, M. J. Ellis, A. Stopeck, J. Matera, M. C. Miller, G. V. Doyle, W. J. Allard, L. W. Terstappen, and D. F. Hayes

Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis
J Clin Oncol (Meeting Abstracts) 2005 23: 524. [Abstract]  

H. S. Rugo, M. N. Dickler, J. H. Scott, D. H. Moore, M. Melisko, B. M. Yeh, J. Caravelli, E. Brogi, C. Hudis, and J. W. Park

Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation
J Clin Oncol (Meeting Abstracts) 2005 23: 525. [Abstract]  

F. M. Boccardo, A. Rubagotti, M. Puntoni, P. Guglielmini, M. Porpiglia, M. Mesiti, M. Rinaldini, G. Paladini, V. Distante, R. Franchi other ITA trialists

Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial
J Clin Oncol (Meeting Abstracts) 2005 23: 526. [Abstract]  

R. Jakesz, H. Samonigg, R. Greil, M. Gnant, M. Schmid, W. Kwasny, E. Kubista, B. Mlineritsch, C. Tausch, M. Stierer on behalf of the ABCSG

Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)
J Clin Oncol (Meeting Abstracts) 2005 23: 527. [Abstract]  

M. Valentini, M. Belfiglio, F. Pellegrini, M. Sacco, A. Nicolucci on behalf of GIVIO Group

Updated results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group for Cancer Care Evaluation study of adjuvant treatment in breast cancer 01 (SITAM 01)
J Clin Oncol (Meeting Abstracts) 2005 23: 528. [Abstract]  

H. J. Burstein, E. P. Winer, K. M. Kuntz, J. C. Weeks, and R. S. Punglia

Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors
J Clin Oncol (Meeting Abstracts) 2005 23: 529. [Abstract]  

V. Semiglazov, A. Kletsel, V. Semiglazov, E. Zhiltzova, V. Ivanov, G. Dashyan, A. Bozhok, O. Melnikova, R. Paltuev, and L. Berstein

Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0)
J Clin Oncol (Meeting Abstracts) 2005 23: 530. [Abstract]  

P. E. Lonning, J. Geisler, L. E. Krag, L. Ottestad, T. Risberg, A. I. Hagen, E. Schlichting, E. Di Salle, A. Polli, and J. Paolini

Changes in bone metabolism after 2 years’ treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: Follow-up (FU) results of a randomized placebo-controlled study
J Clin Oncol (Meeting Abstracts) 2005 23: 531. [Abstract]  

A. Lipton, Y. Hei, R. Coleman, P. Major, and R. Cook

Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome
J Clin Oncol (Meeting Abstracts) 2005 23: 532. [Abstract]  

A. Brufsky, W. G. Harker, J. T. Beck, R. Carroll, E. Tan-Chiu, C. Seidler, L. Lacerna, E. Thomas, E. Perez The Z-FAST Study Group

Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial
J Clin Oncol (Meeting Abstracts) 2005 23: 533. [Abstract]  

J.-J. Body, M. Lichinitser, S. A. Tjulandin, M. Budde, and B. Bergström

Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: Results from a comparative phase III trial
J Clin Oncol (Meeting Abstracts) 2005 23: 534. [Abstract]  

E. McCloskey, A. H. G. Paterson, and T. J. Powles

Oral clodronate maintains bone mass in women with primary breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 535. [Abstract]  

R. Sainsbury, T. J. Perren, S. R. Brown, V. L. Morrell, M. Dowsett, and H. C. Thorpe

Does timing of breast cancer surgery in relation to the menstrual cycle phase affect prognosis? The Yorkshire Breast Cancer Group Intervention, Timing and Survival Study
J Clin Oncol (Meeting Abstracts) 2005 23: 536. [Abstract]  

S. M. Swain, S. R. Land, R. Sundry, M. Ritter, J. Costantino, N. Wolmark, and P. A. Ganz

Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) docetaxel (T) arm of NSABP B-30: Preliminary results
J Clin Oncol (Meeting Abstracts) 2005 23: 537. [Abstract]  

J. A. Petrek, D. Case, E. D. Paskett, E. Naftalis, and M. J. Naughton

Incidence, time course and determinants of menstrual bleeding after breast cancer treatments: A prospective study
J Clin Oncol (Meeting Abstracts) 2005 23: 538. [Abstract]  

K. H. Oktay, N. Libertella, E. Buyuk, K. Lostritto, A. Vickers, and M. Akar

Letrozole and tamoxifen as safer ovarian stimulants in women undergoing embryo cryopreservation for fertility preservation before breast cancer chemotherapy: A prospective controlled trial
J Clin Oncol (Meeting Abstracts) 2005 23: 539. [Abstract]  

P. H. Johnson, K. Gwyn, N. Gordon, L. Middleton, H. Kuerer, P. George, W. Yang, G. Hortobagyi, and R. Theriault

The treatment of pregnant women with breast cancer and the outcomes of the children exposed to chemotherapy in utero
J Clin Oncol (Meeting Abstracts) 2005 23: 540. [Abstract]  

L. Montgomery, L. Dauer, I. Doddamane, J. St. Germain, P. Zanzonico, H. Cody, P. Borgen, and C. Divgi

Assessment of fetal radiation dose during maternal sentinel lymph node mapping for breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 541. [Abstract]  

A. I. So, B. Eigl, L. Fazli, D. Hunstman, N. Ivanonv, M. Pollak, S. Dunn, and M. Gleave

Significance of insulin-like growth factor binding protein-2 in the prognosis of breast cancer and promotion of accelerated growth and chemo-resistance in MDAMB-231 breast cancer model
J Clin Oncol (Meeting Abstracts) 2005 23: 542. [Abstract]  

J. C. Chang, S. Cleator, A. Tsimelzon, A. Ashworth, M. Dowsett, T. Powles, H. Wong, C. K. Osborne, P. O’Connell, and S. Hilsenbeck

Gene expression arrays for the prediction of response to doxorubicin and cyclophosphamide (AC) in human breast cancers
J Clin Oncol (Meeting Abstracts) 2005 23: 543. [Abstract]  

A. Makris, S. G. Hisenbeck, D. Yee, K. C. Osborne, R. M. Elledge, M. Harrison, P. J. Ostler, S. Mohsin, C. M. Gutierrez, and J. C. Chang

A prospective randomized multicenter gene expression study of docetaxel vs doxorubicin/cyclophosphamide preoperative trial in primary breast cancers
J Clin Oncol (Meeting Abstracts) 2005 23: 544. [Abstract]  

L. N. Harris, C. Perou, Z. Szallasi, A. Eklund, S. Carter, F. You, G. Broadwater, L. Monovich, E. Winer, M. Erlander, and M. Ellis

Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342
J Clin Oncol (Meeting Abstracts) 2005 23: 545. [Abstract]  

W. F. Symmans, C. Sotiriou, K. S. Anderson, V. Valero, D. J. Booser, K. R. Hess, J. S. Ross, M. Piccart, G. N. Hortobagyi, and L. Pusztai

Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 546. [Abstract]  

B. Ryan, G. Konecny, S. Kahlert, H. Wang, J. Crown, M. Untch, M. Pegram, D. J. Slamon, and M. J. Duffy

Survivin protein expression predicts poor outcome in patients with primary breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 547. [Abstract]  

J. F. Holland, Y. Wang, S. Mellana, J. Jiang, and B. Pogo

Identification of a retrovirus in human breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 548. [Abstract]  

J. F. R. Robertson, C. Chapman, K.-L. Cheung, A. Murray, S. E. Pinder, M. R. Price, and R. L. Graves

Autoantibodies in early breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 549. [Abstract]  

M. Litwiniuk, J. Breborowicz, V. Filas, J. Moczko, D. Godlewski, M. Stawicka, and R. Kaleta

Expression of estrogen receptors alfa and beta (ERa and ERb) in hereditary breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 550. [Abstract]  

G. Serrero, K. H. Tkaczuk, L. Jones, O. Goloubeva, N. S. Tait, F. S. Feldman, and H. Dai

PC-cell derived growth factor (PCDGF/GP88): A novel circulating biomarker in breast cancer (BC) patients
J Clin Oncol (Meeting Abstracts) 2005 23: 551. [Abstract]  

A. Polychronis, H. D. Sinnett, D. Hadjiminas, H. Singhal, J. L. Mansi, S. Ali, M. J. Slade, S. Shousha, K. Morrisson, and R. C. Coombes

Anti-proliferative and molecular effects of neoadjuvant (pre-operative) gefitinib alone or in combination with anastrozole in epidermal growth factor receptor (EGFR) positive, estrogen receptor alpha (ER) positive patients with primary breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 552. [Abstract]  

A. Mukherjee

The use of ErbB/HER activation status as prognostic markers in breast cancer patients treated with trastuzumab
J Clin Oncol (Meeting Abstracts) 2005 23: 553. [Abstract]  

S. S. Jewell, L. E. Morrison, L. Usha, B. A. Blondin, R. D. Rao, B. Tabesh, M. Kemper, M. Batus, and J. S. Coon

Effects of chromosomes 1, 3, 10 and 17 alterations on patient response to trastuzumab in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 554. [Abstract]  

J.-M. Extra, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, and M. Marty

Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 555. [Abstract]  

E. A. Perez, V. J. Suman, N. E. Davidson, P. A. Kaufman, S. Martino, S. R. Dakhil, J. N. Ingle, R. J. Rodeheffer, B. J. Gersh, D. W. Hillman, and A. S. Jaffe

Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial
J Clin Oncol (Meeting Abstracts) 2005 23: 556. [Abstract]  

N. Spector, L.-H. Liu, C. Gerard, P. N. Baudson, T. Ory, P. Ho, and W. Xia

Combining lapatinib (GW572016) with anti-erbB2 antibodies elicits synergistic apoptotic effects in erbB2 overexpressing breast cancer cells
J Clin Oncol (Meeting Abstracts) 2005 23: 557. [Abstract]  

A. D. Seidman, G. Broadwater, W. Carney, L. Dressler, D. Berry, L. Norton, C. Hudis, E. Winer, M. Ellis, and L. Harris

Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840
J Clin Oncol (Meeting Abstracts) 2005 23: 558. [Abstract]  

A. M. Storniolo, H. Burris, M. Pegram, B. Overmoyer, K. Miller, S. Jones, P. Silverman, E. Paul, J. Loftiss, and L. Pandite

A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen
J Clin Oncol (Meeting Abstracts) 2005 23: 559. [Abstract]  

K. N. Bhalla, P. Bali, M. Pranpat, W. Fiskus, F. Guo, C. Sigua, and R. Swaby

Molecular mechanisms of underlying synergistic effect of combinations of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) with docetaxel and trastuzumab against human breast cancer cells
J Clin Oncol (Meeting Abstracts) 2005 23: 560. [Abstract]  

F. Y. Lee, S. Castaneda, I. Inigo, D. Kan, B. Paul, M.-L. Wen, C. Fairchild, E. Clark, and H. Lee

Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers
J Clin Oncol (Meeting Abstracts) 2005 23: 561. [Abstract]  

S. Vukelja, J. O’Shaughnessy, S. Campos, L. Vahdat, J. Blum, D. Yardley, P. Mainwaring, F. Senecal, R. Benner, L. Denis, and E. Perez

Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results
J Clin Oncol (Meeting Abstracts) 2005 23: 562. [Abstract]  

K. D. Miller, H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, M. D. Pegram, P. D. Eisenberg, M. Collier, B. J. Adams, and C. M. Baum

Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2005 23: 563. [Abstract]  

J. T. Carpenter, H. Roché, M. Campone, R. Colomer, A. Jagiello-Gruszfeld, L. Moore, M. D’Amore, S. Kong, J. Boni, and J. Baselga

Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 564. [Abstract]  

V. Dieras, V. Valero, S. Limentani, G. Romieu, M. Tubiana-Hulin, A. Lortholary, J.-M. Ferrero, P. Kaufman, A. Buchbinder, and M. Besenval

Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): Final results
J Clin Oncol (Meeting Abstracts) 2005 23: 565. [Abstract]  

L. Maiorino, G. Frasci, G. D’Aiuto, P. Comella, R. Thomas, M. Di Bonito, G. Iodice, M. D’Aiuto, M. R. Rubulotta, and G. Comella

A two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study
J Clin Oncol (Meeting Abstracts) 2005 23: 566. [Abstract]  

J. Gralow, S. Green, D. Lew, W. Barlow, K. Dammann, G. Somlo, S. Rivkin, S. Taylor, L. Wong, and R. Livingston

SWOG S0102: A phase II study of docetaxel (DOC) and vinorelbine (VNR) + filgrastim for HER-2 negative, stage IV breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 567. [Abstract]  

T. Hamaoka, J. E. Madewell, C. M. Costelloe, R. Islam, G. Rondon, G. D. Ayers, R. E. Champlin, D. A. Berry, G. N. Hortobagyi, and N. T. Ueno

Accurate response assessment of breast cancer bone metastasis using computed tomography and new response criteria
J Clin Oncol (Meeting Abstracts) 2005 23: 568. [Abstract]  

D. J. Booser, N. T. Ueno, G. Rondon, P. A. Williams, R. Wendt, G. N. Hortobagyi, D. A. Podoloff, and R. E. Champlin

Complete response of bone-only metastatic breast cancer to skeletal: Targeted radiotherapy with ¹⁶⁶HOLMIUM-DOTMP
J Clin Oncol (Meeting Abstracts) 2005 23: 569. [Abstract]  

H. Tsuda, M. Kurozumi, F. Akiyama, G. Sakamoto, S. Noguchi, Y. Takatsuka, T. Watanabe, S. Imoto, and H. Inaji

Histopathological assessment of anastrozole versus tamoxifen as preoperative treatment in postmenopausal women with T2–4b, N0–2, M0 breast cancer: Results from a randomized, double-blind study
J Clin Oncol (Meeting Abstracts) 2005 23: 570. [Abstract]  

S. Chia, J. Ragaz, N. Makretsov, M. Cheang, M. Hayes, B. Gilks, A. Harris, J. Spinelli, K. Gelmon, I. Olivotto, and D. Huntsman

Carbonic anhydrase IX (CA IX) as a predictive marker for benefit from post-mastectomy adjuvant locoregional radiation (RT): Results from the British Columbia (BC) Randomized Radiation Trial
J Clin Oncol (Meeting Abstracts) 2005 23: 571. [Abstract]  

S. I. Bearman, S. Green, J. Gralow, W. Barlow, C. Hudis, A. Wolff, J. Ingle, G. Hortobagyi, R. Livingston, and S. Martino

SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with 4 involved axillary lymph nodes
J Clin Oncol (Meeting Abstracts) 2005 23: 572. [Abstract]  

A. Katz, I. Gage, S. Evans, M. Shaffer, T. Fleury, P. Petrucci, F. Smith, M. Palmer, R. Flax, C. Drogula, and C. Magnant

Can axillary dissection be avoided in patients with sentinel lymph node (SLN) metastases (mets)?
J Clin Oncol (Meeting Abstracts) 2005 23: 573. [Abstract]  

F. Morales-Vasquez, A. M. Gonzalez-Angulo, H. N. López-Basave, D. Córtes, K. Broglio, A. Alvarado, D. Gallardo, A. Mohar, J. Delagarza, G. N. Hortobagyi, and F. Lara

A randomized study of adjuvant chemotherapy for malignant phyllodes tumours of the breast
J Clin Oncol (Meeting Abstracts) 2005 23: 574. [Abstract]  

P. Sukumvanich, J. A. Petrek, M. J. Naughton, and D. Case

Incidence and time course of bleeding after long term amenorrhea following breast cancer treatment: A prospective study
J Clin Oncol (Meeting Abstracts) 2005 23: 575. [Abstract]  

J. de la Garza Salazar, F. Içli, T. Pienkowski, M. Aapro, G. Hortobagyi, M. Martin, M. Piccart, G. Sledge, K. Pritchard, K. Albain on behalf of the ABREAST Investigators

ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 576. [Abstract]  

D. Cella, L. Fallowfield on behalf of the ATAC Trialists’ Group

Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial
J Clin Oncol (Meeting Abstracts) 2005 23: 577. [Abstract]  

M. Sun, M. Sun, J. Lyons-Weiler, A. E. Lokshin, F. Modugno, J. Marks, and W. L. Bigbee

Serum proteomic profiling distinguishes estrogen receptor (ER) positive and ER negative breast cancers
J Clin Oncol (Meeting Abstracts) 2005 23: 578. [Abstract]  

J. H. Kim, V. Bossuyt, D. Lannin, and B. G. Haffty

COX-2 expression in post-mastectomy chest wall relapse
J Clin Oncol (Meeting Abstracts) 2005 23: 579. [Abstract]  

G. Frasci, G. D’Aiuto, P. Comella, A. Siani, R. Thomas, G. Botti, F. Avino, G. Iodice, T. Petrosino, and G. Comella

Weekly cisplatin-epirubicin-paclitaxel with G-CSF support (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Final results of the 9908 SICOG trial
J Clin Oncol (Meeting Abstracts) 2005 23: 580. [Abstract]  

S. Chan, G. Romieu, J. Huober, T. Delozier, M. Tubiana –Hulin, A. Lluch, A. Schneeweiss, A. Llombart, E. Carrasco, and P. Fumoleau

Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study
J Clin Oncol (Meeting Abstracts) 2005 23: 581. [Abstract]  

J. Houghton on behalf of the ATAC Trialists’ Group

Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: Updated data from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial
J Clin Oncol (Meeting Abstracts) 2005 23: 582. [Abstract]  

D. J. Goldfrank, J. Lee, N. D. Kauff, K. E. Hurley, L. M. Balistreri, J. Hellawell, P. I. Borgen, C. A. Hudis, K. Offit, and M. E. Robson

Adherence to mammogram (MMG) screening guidelines in BRCA1/2 mutation carriers
J Clin Oncol (Meeting Abstracts) 2005 23: 583. [Abstract]  

A. Doshi, S. B. Wedam, D. M. Thomasson, R. M. Garcia-Eulate, B. J. Wise, J. Yao, S. M. Steinberg, D. J. Liewehr, P. Choyke, and S. M. Swain

Dynamic contrast enhanced MRI (DCE-MRI) as a potential predictor of clinical response in patients with inflammatory breast cancer (IBC)
J Clin Oncol (Meeting Abstracts) 2005 23: 584. [Abstract]  

A. Ruiz, A. Lluch, M. Martín, B. Munárriz, A. Antón, E. Alba, P. Martínez Del Prado, A. Plazaola, A. Fernández-Aramburo, and E. Mahillo

Spanish Breast Cancer Research Group (GEICAM) population-based study on breast cancer outcomes: El Álamo project (1990–1997)
J Clin Oncol (Meeting Abstracts) 2005 23: 585. [Abstract]  

A. Llombart Cussac, J. Baselga, G. Manikhas, E. Kubista, G. Steger, S. M. Galbraith, M. A. Sullivan, K. Zerba, H. Lee, and L. Gianni

Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data
J Clin Oncol (Meeting Abstracts) 2005 23: 586. [Abstract]  

A. Chan, L. Petruzelka, M. Untch, M. Martin, M. Gil Gil, V. Guillem Porta, M. Z. Wojtukiewicz, A. Stewart, D. Aubert, and J. Gasmi

Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts)
J Clin Oncol (Meeting Abstracts) 2005 23: 587. [Abstract]  

N. Khakpour, A. Lucci, M. Yi, F. Meric-Bernstam, H. M. Kuerer, G. V. Babiera, M. I. Ross, T. Buchholz, A. Garg, and K. K. Hunt

Sentinel lymph node dissection provides similar local-regional control compared to axillary dissection in patients with node negative breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 588. [Abstract]  

E. Baldini, A. Camerini, T. Prochilo, F. Pasqualetti, C. Orlandini, A. Capodanno, B. Salvadori, and P. Collecchi

Cyclin A overexpression and survival in node-negative (N-) breast cancer patients
J Clin Oncol (Meeting Abstracts) 2005 23: 589. [Abstract]  

J. Mortimer, W. Bardwell, S. Blair, and Y. Podbelewicz-Schuller

Correlation between hemoglobin and quality of life in women undergoing adjuvant chemotherapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 590. [Abstract]  

M. Jahanzeb, A. Brufsky, J. Erban, D. Lewis, and S. Limentani

Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support
J Clin Oncol (Meeting Abstracts) 2005 23: 591. [Abstract]  

A. Hafner, R. Robinson, L. Massa, J. Maddox, C. Hoskins, S. Morgan, and T. Reid

Combined modality treatment of lymphedema using the Reid Sleeve and the BioCompression/Optiflow System
J Clin Oncol (Meeting Abstracts) 2005 23: 592. [Abstract]  

F. Montemurro, M. Donadio, M. Clavarezza, S. Redana, G. Vietti Ramus, A. Durando, M. E. Iacomuzzi, R. Ponzone, G. Valabrega, M. Venturini, and M. Aglietta

Outcome of patients with HER2+ advanced breast cancer (ABC) progressing during trastuzumab (T)-based treatment
J Clin Oncol (Meeting Abstracts) 2005 23: 593. [Abstract]  

B. Leyland-Jones, J. Baselga, J. Latreille, A. Wardley, and S. Lennon

A novel loading regimen for trastuzumab in MBC: Boost serum levels in early cycles
J Clin Oncol (Meeting Abstracts) 2005 23: 594. [Abstract]  

P. K. Marcom, C. Isaacs, L. Harris, M. Bryant, A. Kommareddy, Y. Tao, G. Mann, and M. J. Ellis

A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results
J Clin Oncol (Meeting Abstracts) 2005 23: 596. [Abstract]  

Y. Nieto, J. Woods, R. B. Jones, E. J. Shpall, S. I. Bearman, A. E. Baron, and S. Nawaz

Prognostic analysis of intratumor microvessel density (MVD) and vascular endothelial growth factor (VEGF) in high-risk primary breast cancer (HRPBC) patients (PTS) receiving high-dose chemotherapy (HDC)
J Clin Oncol (Meeting Abstracts) 2005 23: 597. [Abstract]  

S. Donnell, A. M. Leitch, D. Rice, E. Gray, D. McKindles, R. Aravind, M. Warungi, F. Youssefi, C. Osborne, and D. Tripathy

Navigator program for breast cancer trial recruitment and enrollment at a county hospital
J Clin Oncol (Meeting Abstracts) 2005 23: 598. [Abstract]  

S. Delaloge, R. Rouzier, L. Pusztai, F. Andre, J.-R. Garbay, M. Spielmann, M.-C. Mathieu, V. Valero, and G. N. Hortobagyi

Predictive and prognostic nomograms for breast cancer treated with primary chemotherapy (PC)
J Clin Oncol (Meeting Abstracts) 2005 23: 599. [Abstract]  

P. E. Goss, S. Qi, H. Hu, A. M. Cheung, W. Lang, D. G. Blanchett, and P. J. Langecker

The effects of atamestane, toremifene, and atamestane plus toremifene compared to letrozole on bone, serum lipids and uterus
J Clin Oncol (Meeting Abstracts) 2005 23: 600. [Abstract]  

M. Morrow, S. J. Katz, P. M. Lantz, N. K. Janz, A. Fagerlin, K. Schwartz, L. Liu, D. Deapen, B. Salem, and I. Lakhani

Surgeon perspectives on local therapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 601. [Abstract]  

P. Carlini, E. Bria, G. Ferretti, A. Felici, P. Papaldo, A. Fabi, E. M. Ruggeri, F. Cognetti, E. Terzoli, and D. Giannarelli

New aromatase inhibitors (Ais) as 1st-line endocrine therapy (ET) in metastatic breast cancer (MBC): A pooled analysis of 3238 women from 8 phase III trials
J Clin Oncol (Meeting Abstracts) 2005 23: 602. [Abstract]  

L. A. Habel, C. P. Quesenberry, M. Jacobs, D. Greenberg, L. Fehrenbacher, C. Alexander, J. Baker, D. Watson, J. Hackett, and S. Shak

Gene expression and breast cancer mortality in Northern California Kaiser Permanente Patients: A large population-based case control study
J Clin Oncol (Meeting Abstracts) 2005 23: 603. [Abstract]  

M. Martin, A. Lluch, M. Á. Seguí, A. Antón, C. Fernández-Chacón, A. Ruíz, M. Ramos, E. Adrover, Á. Rodríguez-Lescure, and A. Casado

Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GEICAM Study 9805
J Clin Oncol (Meeting Abstracts) 2005 23: 604. [Abstract]  

H. H. Roche, F. M. Penault-Llorca, C. Sagan, M. Lacroix-Triki, Y. Denoux, V. Verriele, J. Jacquemier, M.-C. Baranzelli, F. Bibeau, and A.-L. Martin

Prognostic and predictive value of HER2, PR, ER, and KI67 in the PACS01 trial comparing epirubicin-based chemotherapy to sequential epirubicin followed by docetaxel
J Clin Oncol (Meeting Abstracts) 2005 23: 605. [Abstract]  

J. Abraham, M. W. Haut, M. T. Moran, S. Filburn, M. P. Iannetti, S. Lemiuex, and H. Kuwabara

The effect of chemotherapy for breast cancer on cerebral white matter: A diffusion tensor imaging study
J Clin Oncol (Meeting Abstracts) 2005 23: 606. [Abstract]  

J. Y. Pierga, S. J. Cleator, J. S. Reis-Filho, T. Dexter, A. Mackay, P. Simpson, A. Ashworth, I. E. Smith, T. Powles, and M. Dowsett

MicroArrays comparative genomic hybridisation (aCGH) and response to neoadjuvant chemotherapy (CT) in breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2005 23: 607. [Abstract]  

A. U. Buzdar on behalf of the ATAC Trialists’ group

Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial
J Clin Oncol (Meeting Abstracts) 2005 23: 608. [Abstract]  

L. B. Michaud, E. Rivera, T. Madden, L. Esparza-Guerra, D. J. Booser, M. C. Green, G. R. Bradshaw, G. N. Hortobagyi, and V. Valero

Taxanes in metastatic breast cancer patients with impaired liver function
J Clin Oncol (Meeting Abstracts) 2005 23: 609. [Abstract]  

S. E. Jones, J. Cantrell, S. Vukelja, J. Pippen, J. O’Shaughnessy, J. L. Blum, R. Brooks, S. Mull, D. Ilegbodu, and L. Asmar

The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 610. [Abstract]  

N. Denduluri, S. B. Wedam, S. X. Yang, A. Parr, A. Berman, S. Steinberg, and S. M. Swain

Effect of bevacizumab and chemotherapy on serum levels of sVCAM-1 in patient with inflammatory and locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 611. [Abstract]  

M. Baum, J. Cuzick, A. Howell, A. Buzdar, R. Demicheli, M. Greco, M. Retsky, B. Hrushesky on behalf of the ATAC Trialists’ Group and the Milan Institute

An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the ’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database
J Clin Oncol (Meeting Abstracts) 2005 23: 612. [Abstract]  

U. Michael, C. Jackisch, M. S. Lenhard, A. Du Bois, H.-J. Lueck, C. Thomssen, W. Kuhn, C. Kurbacher, U. Nitz, R. Kreienberg, and V. J. Möbus

Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC)
J Clin Oncol (Meeting Abstracts) 2005 23: 613. [Abstract]  

B. Hennessy, S. Giordano, K. Broglio, G. N. Hortobagyi, and V. Valero

Sarcomatoid (metaplastic) carcinoma of the breast: The U.T. M.D. Anderson Cancer Center (MDACC) and SEER database experience
J Clin Oncol (Meeting Abstracts) 2005 23: 614. [Abstract]  

R. Hass, A. Scharf, H.-J. Lück, and H. Kühnle

Estrogen-induced phosphorylation of P53 at Ser15 in aging HMEC in the absence of estrogen receptor
J Clin Oncol (Meeting Abstracts) 2005 23: 615. [Abstract]  

M. N. Fornier, A. D. Seidman, D. Lake, G. D’Andrea, J. Bromberg, M. Robson, C. H. van Poznak, K. Panageas, L. Norton, and C. Hudis

Increased dose-density (DD) Is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10–11 day interval with filgrastim support, for women with early breast carcinoma (BC)
J Clin Oncol (Meeting Abstracts) 2005 23: 616. [Abstract]  

N. S. Wong, H. J. Kahn, L. Y. Zhang, S. Oldfield, L. Y. Yang, A. Marks, and M. Trudeau

Circulating tumour cells (CTC) in breast cancer patients enumerated after filtration enrichment: Evaluation of prognostic significance
J Clin Oncol (Meeting Abstracts) 2005 23: 617. [Abstract]  

P. Stieber, H. J. Roth, J. Stemmler, H. Schmidt, M. Untch, B. Liedl, R. Hatz, D. Nagel, and V. Heinemann

The pattern of HER-2/neu release in benign and malignant diseases
J Clin Oncol (Meeting Abstracts) 2005 23: 618. [Abstract]  

M. Paley, N. Love, R. Carlson, D. Tripathy, R. Kaderman, D. Paley, J. Dvorkin, and K. Ziel

Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 619. [Abstract]  

M. L. Citron, D. A. Berry, C. Cirrincione, R. B. Livingston, W. Gradishar, E. Perez, H. Muss, L. Norton, E. Winer, and C. Hudis

Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG
J Clin Oncol (Meeting Abstracts) 2005 23: 620. [Abstract]  

R. A. Beveridge, N. J. Robert, S. Desai, and R. McCormack

Early assessment of circulating tumor cell results in a community-based practice
J Clin Oncol (Meeting Abstracts) 2005 23: 621. [Abstract]  

M. Ryberg, D. Nielsen, G. Nielsen, and T. Skovsgaard

Outcome for breast cancer patients with congestive heart failure after epirubicin treatment
J Clin Oncol (Meeting Abstracts) 2005 23: 622. [Abstract]  

R. Rouzier, F. Andre, R. Arriagada, L. Pusztai, M. Spielmann, M.-C. Mathieu, H. Marsiglia, A. Dunant, G. N. Hortobagyi, and S. Delaloge

Individual benefits from adjuvant anthracycline-based chemotherapy can be predicted from a predictive nomogram created from primary chemotherapy (PC) data: Results of a randomized trial
J Clin Oncol (Meeting Abstracts) 2005 23: 623. [Abstract]  

M. Chaudhry, M. Schnall, A. Alavi, and M. Putt

Multimodality detection of multicentric breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 624. [Abstract]  

J. S. Gurtler, L. Goldstein, S. Delprete, S. Tjulandin, V. Semiglazov, L. Sternas, B. Michiels, and E. Gilles

Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens
J Clin Oncol (Meeting Abstracts) 2005 23: 625. [Abstract]  

R. Simon, A. Kaur, P. Schraml, H. Novotny, M. Mirlacher, and G. Sauter

High concordance of HER-2/neu gene amplification and overexpression in hematogeneous breast cancer metastases
J Clin Oncol (Meeting Abstracts) 2005 23: 626. [Abstract]  

D. Skarlos, H. Gogas, V. Kiriakou, A. Margariti, E. Kirkou, K. Pavlaki, A. Asimaki, T. Toliou, D. Tziortziotis, C. Vamvouka, and G. Fountzilas

Evaluation of the prognostic value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy (DSAC)
J Clin Oncol (Meeting Abstracts) 2005 23: 627. [Abstract]  

G. K. Ellis, T. Thompson, H. M. Linden, K. Rinn, A. E. Murphy, J. R. Gralow, and R. B. Livingston

Adjuvant weekly "AC+G" followed by weekly paclitaxel shows good efficacy in node-positive breast cancer at two years median follow-up
J Clin Oncol (Meeting Abstracts) 2005 23: 628. [Abstract]  

S. R. Gorla, J. Steel, R. Cohn, and S. A. Khan

Impact of surgical resection of primary breast tumor in stage IV breast cancer on local control and survival
J Clin Oncol (Meeting Abstracts) 2005 23: 629. [Abstract]  

C. Palmieri, T. Macgregor, S. Girgis, and D. M. Vigushin

Serum 25 hydroxyvitamin D levels in early and advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 630. [Abstract]  

K. Pachmann, J. H. Clement, K. Hoeffken, C.-P. Schneider, K. Lobodasch, O. Camara, and U. Pachmann

Quantitative monitoring of circulating epithelial cells for individual therapy control in lung and breast cancer during neoadjuvant treatment, surgery and adjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2005 23: 631. [Abstract]  

L. J. Adepoju, W. F. Symmans, G. V. Babiera, S. E. Singletary, N. Sneige, T. A. Buchholz, K. K. Hunt, F. Meric-Bernstam, B. Arun, and H. M. Kuerer

The clinical impact of proliferative high-risk lesions presenting concurrently with ductal carcinoma in situ (DCIS) in patients (pts) treated with breast conserving therapy (BCT)
J Clin Oncol (Meeting Abstracts) 2005 23: 632. [Abstract]  

S. L. Tam, J. R. Gralow, R. B. Livingston, H. M. Linden, G. K. Ellis, E. K. Schubert, L. K. Dunnwald, and D. A. Mankoff

Serial FDG-PET to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
J Clin Oncol (Meeting Abstracts) 2005 23: 633. [Abstract]  

L. Lamerato, S. Havstad, S. Gandhi, and D. Jones

Costs of initial, continuing and terminal care in US patients with recurrence following early breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 634. [Abstract]  

E. Espinosa, P. Cejas, A. Redondo, J. A. Fresno, D. Hardisson, E. Casado, and M. González Barón

Phospholipid hydroperoxide gluthatione peroxidase overexpression is associated with a poor overall survival in human breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 635. [Abstract]  

M. J. Naughton, J. A. Petrek, E. Ip, E. D. Paskett, and E. Naftalis

Health-related quality of life of pre-menopausal breast cancer survivors
J Clin Oncol (Meeting Abstracts) 2005 23: 636. [Abstract]  

W. P. O’Meara, A. D. Seidman, Y. Yamada, B. McCormick, S. Diamond, P. H. Gutin, and A. Narayana

Impact of HER2 status in breast cancer patients receiving stereotactic radiosurgery for brain metastases
J Clin Oncol (Meeting Abstracts) 2005 23: 637. [Abstract]  

D. I. Luftner, S. Schildhauer, H. Eggemann, R. Geppert, K. Wernecke, M. Weigand, M. Budner, T. Zeiser, A. Kohls, K. Possinger, and D. Elling

Upregulation of HER-2/neu is independent of the menopausal status of primary breast cancer patients: Plasma results from a prospectively randomized trial comparing dose-intense chemotherapy with G-CSF support to 3-weekly chemotherapy for adjuvant therapy of nodal-positive (1–3 LN) breast cancer (German Adjuvant Study Group ASG)
J Clin Oncol (Meeting Abstracts) 2005 23: 638. [Abstract]  

M. A. Koike Folgueira, H. P. Brentani, D. F. Padrao, D. M. Carraro, M. L. H. Katayama, L. D. Mota, E. M. Barbosa, C. T. Oliveira, M. M. Netto, and M. M. Brentani

Expression profile of residual breast cancer after primary chemotherapy based on doxorubicin
J Clin Oncol (Meeting Abstracts) 2005 23: 639. [Abstract]  

A. Monnier, M. Marty, M. Espié, and T. Delozier

The use of dexrazoxane as a cardioprotectant in patients receiving epirubicin-based chemotherapy for metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 640. [Abstract]  

S. Saji, M. Kawakami, S.-I. Hayashi, S.-I. Horiguchi, M. Yoshida, S. L. Schreiber, and M. Toi

Utility of Histone deacetylase 6, a novel estrogen regulated gene affecting cell motility, as predictive factor for adjuvant endocrine treatment and as therapeutic target
J Clin Oncol (Meeting Abstracts) 2005 23: 641. [Abstract]  

C. Luk, P. Goss, K. Pritchard, T. J. Whelan, S. Liu, L. Shepherd, and J. Pater

Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen
J Clin Oncol (Meeting Abstracts) 2005 23: 642. [Abstract]  

S. Pidaparthi

ErbB/Her dimerization in breast and lung cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 643. [Abstract]  

D. L. Graham, D. W. Hillman, T. J. Hobday, S. R. Rousey, S. G. Nair, G. S. Soori, T. M. Sabagh, and E. A. Perez

N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2005 23: 644. [Abstract]  

R. Dua

ErbB/HER pathway profiling in formalin-fixed paraffin embedded tissues using multiplexed proximity-based assays
J Clin Oncol (Meeting Abstracts) 2005 23: 645. [Abstract]  

A. Rody, T. Karn, M. Munnes, G. von Minckwitz, S. Loibl, C. Solbach, U. Holtrich, and M. Kaufmann

Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, doxorubicin, and cyclophosphamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures
J Clin Oncol (Meeting Abstracts) 2005 23: 646. [Abstract]  

P.-P. Piedbois, D. Serin, F. Priou, P. Laplaige, S. Greget, E. Angellier, E. Teissier, J. F. Berdah, M. Fabbro, B. Valenza Association Europeenne de Recherche en Oncologie (AERO)

AERO-B03: A randomized phase II trial of dose-dense docetaxel in node-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 647. [Abstract]  

A. Krause, W. Janni, T. Reimer, and B. Gerber

Anastrozol (Ana) versus tamoxifen (Tam) treatment in postmenopausal breast cancer women with tamoxifen treatment and abnormal vaginal bleeding: Results from an open-label randomized trial
J Clin Oncol (Meeting Abstracts) 2005 23: 648. [Abstract]  

J. Ragaz, J. J. Spinelli, G. Villeneuve, L. Ellison, and A. Coldman

Mortality reduction of breast cancer in Canada: Beneficial impact of cancer care infrastructure
J Clin Oncol (Meeting Abstracts) 2005 23: 649. [Abstract]  

S. Paluch-Shimon, N. Ben-Baruch, I. Wolf, L. Zach, A. Kruglikova, E. Landau, T. Modiano, R. Weitzen, R. Catane, and B. Kaufman

Breast cancer with HER2/neu over-expression and hormone receptor positive status: A distinct biology and natural history
J Clin Oncol (Meeting Abstracts) 2005 23: 650. [Abstract]  

R. Kramer, Y. L. Tham, K. Sexton, L. Friedman, and H. Weiss

Chemotherapy-induced amenorrhea is increased in patients treated with adjuvant doxorubicin and cyclophosphamide (AC) followed by a taxane (T)
J Clin Oncol (Meeting Abstracts) 2005 23: 651. [Abstract]  

H. H. Helgason, C. M. F. Kruijtzer, A. D. R. Huitema, S. Marcus, W. W. Ten Bokkel-Huinink, M. E. Schot, J. H. Schornagel, J. H. Beijnen, and J. H. M. Schellens

Phase II and pharmacological study of oral paclitaxel plus cyclosporine A in anthracycline pretreated metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 652. [Abstract]  

R. E. Mansel

Cost-utility analysis of anastrozole vs tamoxifen in postmenopausal women with early breast cancer from a UK national health service perspective: The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial
J Clin Oncol (Meeting Abstracts) 2005 23: 653. [Abstract]  

E. J. Sherman, E. M. Lepisto, J. C. Niland, N. Nicotera, R. A. Ottesen, R. L. Theriault, S. B. Edge, J. Wilson, M. A. Bookman, and J. C. Weeks

The addition of taxanes to adjuvant chemotherapy for lymph node positive (N+) early breast cancer (BC): Institutional practice variation in the National Comprehensive Cancer Network (NCCN)
J Clin Oncol (Meeting Abstracts) 2005 23: 654. [Abstract]  

M. L. W. Ah-See, R. J. Burcombe, F. M. Daley, P. I. Richman, A. R. Padhani, S. M. Bentzen, S. B. Fox, A. L. Harris, and A. Makris

Evaluation of tumour microvessel density & pericyte coverage index following neoadjuvant chemotherapy in primary breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 655. [Abstract]  

A. M. Gonzalez-Angulo, E. O. Hanraham, S. H. Giordano, K. Broglio, F. Morales-Vasquez, M. Cristofanilli, V. Valero, R. L. Theriault, and G. N. Hortobagyi

Survival of patients with breast cancer tumors 1 cm or less. Analysis of the Surveillance, Epidemiology and End Results (SEER) Registry
J Clin Oncol (Meeting Abstracts) 2005 23: 656. [Abstract]  

J. J. Lee, J. A. Low, E. Croarkin, R. Parks, A. W. Berman, N. Mannan, S. M. Steinberg, and S. M. Swain

Evaluation of neuropathy in breast cancer patients treated with ixabepilone
J Clin Oncol (Meeting Abstracts) 2005 23: 657. [Abstract]  

J. Cuzick and A. Howell

Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 658. [Abstract]  

M. Klinkhammer-Schalke, W. Lorenz, B. Steinger, C. Jakob, B. Ernst, F. Hofstädter, and M. Koller

Enhancing the status of quality-of-life diagnostics in caring for breast cancer patients: Results from a multilevel implementation study in a regional tumor centre
J Clin Oncol (Meeting Abstracts) 2005 23: 659. [Abstract]  

P. Kerbrat, H. Roche, P. Fumoleau, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, and E. Luporsi

Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results
J Clin Oncol (Meeting Abstracts) 2005 23: 660. [Abstract]  

P. Hopwood, P. Ellis, P. Barrett-Lee, J. M. Bliss, E. Hall, L. Johnson, D. Lawrence, S. Russell, D. Cameron on behalf of the TACT Trial Management Group

Impact on quality of life (QL) during chemotherapy (CT) of FEC-T compared to FEC or E-CMF: Results from the UK NCRI Taxotere as Adjuvant Chemotherapy Trial (TACT)
J Clin Oncol (Meeting Abstracts) 2005 23: 661. [Abstract]  

L. Del Mastro, T. Catzeddu, L. Boni, C. Bighin, S. Pastorino, C. Bell, M. R. Sertoli, M. Clavarezza, D. Testa, and M. Venturini

Temporary ovarian suppression with goserelin for prevention of chemotherapy-induced menopause in young early breast cancer patients: Results of a phase II study
J Clin Oncol (Meeting Abstracts) 2005 23: 662. [Abstract]  

E. O. Hanrahan, D. Frye, A. U. Buzdar, R. L. Theriault, D. J. Booser, V. Valero, S. E. Singletary, J. L. Gajewski, R. E. Champlin, and G. N. Hortobagyi

Twelve-year follow-up of a randomized trial of high-dose chemotherapy (HDC) and autologous hematopoietic stem cell support (ASCS) for high-risk primary breast carcinoma
J Clin Oncol (Meeting Abstracts) 2005 23: 663. [Abstract]  

J. M. Stephens, M. S. Aapro, M. F. Botteman, J. W. Hay, and J. Brandman

A Markov model to evaluate the cost effectiveness of intravenous (IV) zoledronic acid vs IV generic pamidronate or oral ibandronate in the prevention of bone complications in breast cancer patients with bone metastases
J Clin Oncol (Meeting Abstracts) 2005 23: 664. [Abstract]  

S. P. Boyce, B. A. Mincey, M.-S. Duh, M. Marynchenko, M. K. Raut, J. Brandman, and E. A. Perez

Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT)
J Clin Oncol (Meeting Abstracts) 2005 23: 665. [Abstract]  

F. Nolè, C. Catania, G. Sanna, L. Adamoli, K. Imadalou, G. Zorza, A. Bodini, and A. Goldhirsch

Dose finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine in metastatic breast cancer (MBC) patients: Final results
J Clin Oncol (Meeting Abstracts) 2005 23: 666. [Abstract]  

S. Almokadem, K. Leitzel, H. A. Harvey, E. Bannon, S. M. Ali, C. Miller, M. Repollet, W. J. Allard, L. W. W. M. Terstappen, and A. Lipton

Circulating tumor cells in adjuvant breast cancer patients
J Clin Oncol (Meeting Abstracts) 2005 23: 667. [Abstract]  

D. Mavroudis, M. Perraki, G. Kallergi, A. Pallis, P. Kanellou, L. Kalmanti, N. Xenidis, V. Bozionelou, E. Manousakis, and V. Georgoulias

Molecular detection of HER2 mRNA-positive cells in the peripheral blood of patients with operable breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 668. [Abstract]  

S. H. Giordano, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, J. Freeman, and J. S. Goodwin

The impact of CALGB 9344 on adjuvant taxane (T) Use for breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2005 23: 669. [Abstract]  

E. Tanchiu, P. A. Kaufman, S. Paik, M. Ulcickas-Yood, M. Mayer, D. Tripathy, H. Rugo, and A. Brufsky

registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 670. [Abstract]  

A. Fuentes Alburo, E. Dubon, I. Aguirre, V. Pérez, T. A. Vela, A. Mora, and N. A. Hernandez-Rodriguez

Estrogen receptor ß expression in high-grade breast cancer patients may predict metastases and mortality
J Clin Oncol (Meeting Abstracts) 2005 23: 671. [Abstract]  

S. Rodenhuis, M. Bontenbal, L. V. A. M. Beex, D. J. Richel, M. A. Nooij, E. E. Voest, E. van der Wall, P. Hupperets, H. van Tinteren, M. van de Vijver, and E. G. E. de Vries

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: Update of the Dutch Randomized Trial
J Clin Oncol (Meeting Abstracts) 2005 23: 672. [Abstract]  

M. Ghosn, G. Chahine, J. Kattan, F. Farhat, F. Nasr, W. Moukadem, J. Dagher, F. Younes, J. Gasmi Cancer Research Group/Collaborative Group (CRG/CG)

Vinorelbine (N)-capecitabine (C) combination in advanced breast cancer (ABC): Long-term results of two multicentric phase II trials
J Clin Oncol (Meeting Abstracts) 2005 23: 673. [Abstract]  

G. Y. Yang, K. Wharton, T. D. Wagner, K. Donohue, P. Tripp, K. Khaghany, G. Tompson, J. Martin, G. Hare, and W. Jaggernauth

Pure tubular breast carcinoma: A study of outcomes from 1971–2004
J Clin Oncol (Meeting Abstracts) 2005 23: 674. [Abstract]  

Y.-R. Do, H.-S. Song, S. H. Kang, K.-Y. Jung, Y.-S. Kim, J.-L. Lee, and W.-S. Lee

Prognostic significance of immunohistochemical expression of p53 gene product in invasive breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 675. [Abstract]  

S. S. Bacus, J. Hill, G. Hortobagyi, and N. Spector

Mechanism of action associated with response to erbB targeted therapy
J Clin Oncol (Meeting Abstracts) 2005 23: 676. [Abstract]  

L. C. Friedman

Medical and psychosocial predictors of delay in seeking medical consultation for breast symptoms in low-income women
J Clin Oncol (Meeting Abstracts) 2005 23: 677. [Abstract]  

A. Auriemma, A. Mercanti, E. Fiorio, M. Mandarà, M. Giovannini, M. Pavarana, A. Caldara, R. Micciolo, G. L. Cetto, and A. Molino

Invasive breast cancer: Ki-67 evaluation in 3909 early breast cancer patients
J Clin Oncol (Meeting Abstracts) 2005 23: 678. [Abstract]  

S. L. Moulder, P. Munster, S. Minton, N. Diaz, J. Horton, C. Rocha Lima, L. Hutson, and D. Sullivan

Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2005 23: 679. [Abstract]  

R. A. Nagourney, B. Sommers, S. Evans, C. Kollin, Y. Z. Su, T. Evans, J. Islas, J. Kakkis, and L. Tabar

Casting-type calcification breast cancer: Assessment of response to cytotoxic insult in human tumor primary culture spheroids
J Clin Oncol (Meeting Abstracts) 2005 23: 680. [Abstract]  

S.-Y. Kong, Y. Kwon, D. H. Lee, J. S. Lee, E. S. Lee, and J. Ro

The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 681. [Abstract]  

A. Felici, E. Bria, G. Ferretti, P. Carlini, M. Ciccarese, F. L. Cecere, C. Nisticò, F. Cognetti, E. Terzoli, and D. Giannarelli

Taxanes as neoadjuvant chemotherapy (NAC) for breast cancer (BC): Pooled-analysis of 3120 patients (Pts) enrolled in 10 randomized trials (RCTs)
J Clin Oncol (Meeting Abstracts) 2005 23: 682. [Abstract]  

S.-J. J. Dawson, N. F. Ranieri, R. D. Snyder, S.-A. A. McLachlan, W. I. Burns, G. M. Newnham, P. A. Francis, and A. J. Dowling

Trastuzumab (T) and CNS metastases in women with HER-2 positive metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2005 23: 683. [Abstract]  

I. Sachelarie, K. Kerr, S. K. Boolbol, S. N. Gettinger, and R. H. Blum

Impact of PET-CT on initial staging and treatment of breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 684. [Abstract]  

R. Oratz, J. Blum, K. Rowland, C. Cunningham, S. Jacobs, J. Arseneau, D. Richards, F. G. Renshaw, F. Holmes, and J. O’Shaughnessy

A phase II multicenter study of the cell cycle inhibitor indisulam in refractory metastatic breast carcinoma
J Clin Oncol (Meeting Abstracts) 2005 23: 685. [Abstract]  

D. Di Vizio, A. Sboner, F. de Michelis, R. Micciolo, A. Lucenti, A. Ferro, R. Triolo, E. Galligioni, P. Dalla Palma, and M. Barbareschi

Multiple marker analysis in breast tumors with long term follow-up using Tissue Microarray: Immunohistochemical evaluation of ER, PgR, MIB1, p27, p63, HMWCK, FITH, Her2/neu and p53
J Clin Oncol (Meeting Abstracts) 2005 23: 686. [Abstract]  

A. H. Partridge, S. Gelber, R. Gelber, A. Goldhirsch, E. P. Winer International Breast Cancer Study Group

Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V
J Clin Oncol (Meeting Abstracts) 2005 23: 687. [Abstract]  

M. Giovannini, A. Mercanti, E. Fiorio, A. Auriemma, M. Mandara’, M. Frisinghelli, M. Pavarana, R. Micciolo, G. L. Cetto, and A. Molino

How has early invasive breast cancer (BC) changed in the past decade? Analysis of 3615 consecutive patients (pts)
J Clin Oncol (Meeting Abstracts) 2005 23: 688. [Abstract]  

O. Bitisik, P. Saip, S. Saglam, and N. Dalay

Detection of circulating breast cancer cells in relation to therapy
J Clin Oncol (Meeting Abstracts) 2005 23: 689. [Abstract]  

F. Gutman, J.-L. Alberini, F. Lerebours, E. Gonthier, M. Wartski, M. Al Nakib, E. Brain, J.-L. Floiras, and A.-P. Pecking

18-fluorodeoxyglucose positron emission tomography in initial diagnosis and staging of inflammatory breast tumors
J Clin Oncol (Meeting Abstracts) 2005 23: 691. [Abstract]  

A. Stojadinovic, O. Moskovitz, Z. Gallimidi, S. Fields, A. D. Brooks, R. Brem, R. N. Mucciola, M. Singh, and C. D. Shriver

Prospective study of electrical impedance scanning for identifying young women at risk for breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 692. [Abstract]  

Y. Saito, Y. Tokuda, Y. Suzuki, S. Umemura, and R. Y. Osamura

Clinicopathological study of brain metastases in breast cancer patients treated with or without trastuzumab
J Clin Oncol (Meeting Abstracts) 2005 23: 693. [Abstract]  

A. Garin, A. Manikhas, M. Biakhov, M. Chezhin, T. Ivanchenko, K. Krejcy, V. Karaseva, and S. Tjuyandin

A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): Preliminary results
J Clin Oncol (Meeting Abstracts) 2005 23: 694. [Abstract]  

R. A. Buckman, N.-S. Wong, M. Clemons, S. Verma, M. E. Trudeau, K. Roche, R. S. Kerbel, G. Deboer, D. J. Sutherland, and K. I. Pritchard

Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2005 23: 695. [Abstract]  

J. P. Crowe, G. T. Budd, R. J. Patrick, L. A. Rybicki, R. R. Tubbs, and D. Hicks

Clinical correlates of HER2 amplification: A multivariable analysis
J Clin Oncol (Meeting Abstracts) 2005 23: 696. [Abstract]  

M. F. Gaui, G. Amorim, R. Arcuri, G. Pereira, D. Moreira, and C. Djahjah

Capecitabine chemoradiation (X-RT) as neoadjuvant therapy for patients (pts) with locally advanced breast cancer (LABC) refractory to anthracyclines
J Clin Oncol (Meeting Abstracts) 2005 23: 698. [Abstract]  

B. K. Linderholm, J. Lehtio, E. Lidbrink, E. Ekman, P. Karlsson, A. von Wachenfeldt, B. Norberg, L. Carlsson, T. Hatschek, and R. Lewensohn

Protein profiles (proteomics) discriminating between effect/no effect of weekly paclitaxel: A phase II study in metastatic breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2005 23: 699. [Abstract]  

A. Atmaca, S.-E. Al-Batran, H.-G. Meerpohl, E.-M. Grischke, W. Lerbs, A. Knuth, and E. Jäger

PEG-liposomal doxorubicin (PLD) at 40mg/m² versus 50mg/m² every month for patients with metastatic breast cancer: A comparative analysis of two prospective phase II studies
J Clin Oncol (Meeting Abstracts) 2005 23: 700. [Abstract]  

V. Garimella, M. Watson, D. Manton, A. Hubbard, A. Chaturvedi, A. Maraveyas, J. Greenman, P. J. Drew, L. W. Turnbull, M. J. Lind, and L. Cawkwell

Correlation of pre-treatment apoptotic marker expression with response to neo-adjuvant chemotherapy in locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 701. [Abstract]  

A. Vincent-Salomon, J. Y. Pierga, V. Girre, V. Laurence, H. Magdelenat, M. Caly, X. Sastre-Garau, P. Pouillart, P. de Cremoux, and J. P. Thiery

Clinical significance of tumoral cells detection by immunocytochemistry in bone marrow (BM) of metastatic breast cancer (MBC) patients
J Clin Oncol (Meeting Abstracts) 2005 23: 702. [Abstract]  

A. T. Perez, A. Sear, C. Frankel, S. X. Franco, E. Tan-Chiu, F. Gokce, and C. L. Vogel

Acupuncture for the management of hot flashes in women with early stage breast cancer treated with tamoxifen or an aromatase inhibitor: A pilot study of efficacy, safety and feasibility
J Clin Oncol (Meeting Abstracts) 2005 23: 703. [Abstract]  

N. W. Peacock, J. Bearden, F. Schnell, M. White, F. A. Greco, H. A. Burris, J. H. Barton, J. D. Hainsworth, D. R. Spigel, and D. A. Yardley

Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 704. [Abstract]  

M. Hofman, J. T. Hickok, G. R. Morrow, J. A. Roscoe, L. J. Gillies, and S. L. Ranson

Cancer treatment side effects in breast cancer patients receiving radiation therapy
J Clin Oncol (Meeting Abstracts) 2005 23: 705. [Abstract]  

E. Shirdel, M. Korenberg, and Y. Madarnas

Use of fast orthogonal search to predict chemotherapy-induced leukopenia
J Clin Oncol (Meeting Abstracts) 2005 23: 706. [Abstract]  

M. Ramos, J. Casal, A. Galán, C. Almanza, L. León, M. Amenedo, A. Gonzalez, G. Huidobro, and V. Giner

Phase II multicenter sequential study of docetaxel (T) and epirubicin (E) followed by docetaxel (T) and capecitabine (X) as first-line treatment of advanced or metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2005 23: 707. [Abstract]  

G. Steger, R. Bartsch, C. Wenzel, D. Hussian, U. Sevelda, U. Pluschnig, R. Mader, and C. C. Zielinski

Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer: A pilot study
J Clin Oncol (Meeting Abstracts) 2005 23: 708. [Abstract]  

J. E. Freeman, S. Panasyuk, A. E. Rogers, S. Yang, and R. Lew

Advantages of intraoperative medical hyperspectral imaging (MHSI) for the evaluation of the breast cancer resection bed for residual tumor
J Clin Oncol (Meeting Abstracts) 2005 23: 709. [Abstract]  

M. Bahl, M. Ennis, I. F. Tannock, J. E. Hux, K. I. Pritchard, J. Koo, and P. J. Goodwin

The prognostic effect of lipids on early-stage breast cancer (BC) outcome
J Clin Oncol (Meeting Abstracts) 2005 23: 710. [Abstract]  

B. Guix, J. A. Lejarcegui, J. I. Tello, G. Zanon, P. Hugo, J. M. Del-Campo, D. Rubio, L. Marques, and P. Palombo

Fourteen-year results of a non-randomized comparison between a second conservative treatment and mastectomy for locally recurrent breast cancer
J Clin Oncol (Meeting Abstracts) 2005 23: 711. [Abstract]